The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.
The user has tried various hair loss treatments, including topilutamide, alfatradiol, pyrilutamide, and topical spironolactone, but experienced headaches. They are inquiring about the availability and legality of clascoterone in Spain.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.
A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.
Cetirizine 1% cream significantly improves hair growth and thickness in men with androgenic alopecia. It is considered effective, affordable, and has a low side effect profile.
Hair regrowth treatments, including stem cell injections, are discussed, with skepticism about their effectiveness compared to Minoxidil and finasteride. Derma stamping is mentioned as effective when used with Minoxidil, finasteride, and dutasteride.
Stem cell hair transplants use stem cells from fat tissue to reactivate inactive hair follicles, but results are inconsistent and not widely shared. Traditional treatments like finasteride and minoxidil often show better results.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
Clascoterone lotion, being tested in Germany, is as effective as Minoxidil and Finasteride for hair loss but without serious side effects. About 400 men participated in the trials.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.
A user shared their positive experience with hair regrowth using finasteride 1.25 mg daily and dermastamping every two weeks. They reported no side effects and noticed regrowth after about three months.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
Dutasteride can cause hair shedding even with suppressed testosterone levels due to previous damage from DHT. Hair shedding is often a sign of damaged hair being replaced by healthier growth.
A user's 1-year progress using the God Stack, which is a combination of Dutasteride, Finasteride, oral minoxidil, RU58841, derma roller, ketoconazole shampoo, and stemoxydine. No side effects were experienced other than watery semen for the first few months.
The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.
The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.